Palantir Sees Stock Uptick Amid U.S. Tariff Changes

Published 1 days agoPLTR

Palantir Sees Stock Uptick Amid U.S. Tariff Changes

Palantir Technologies Inc. has seen a notable increase in its stock price, reaching $131.78 USD, following changes in U.S. trade policies. The stock closed with a gain of 9.525 (0.07787%) after opening at $123.50 USD. Intraday trading saw the stock range between a high of $131.88 USD and a low of $121.57 USD with a substantial trading volume of 185,897,579 shares.

This stock movement coincided with President Donald Trump’s announcement of plans to double tariffs on imported steel and aluminum from 25% to 50%, effective June 4, 2025. Reuters reported this measure aims to strengthen the U.S. steel industry, though it has prompted concerns about its broader economic impact. As a result, related market movements included a 26% surge in Cleveland-Cliffs Inc.'s shares, reflecting investor interest in domestic steel producers amid the tariff changes.

Given Palantir's involvement in providing data analytics and software to government clients, its operations could be sensitive to shifts in government policy and spending driven by such tariffs. As these developments unfold, market volatility remains a factor for technology stocks like Palantir, emphasizing the importance of closely watching trade policy impacts.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Campbell Soup Sees Boost from Eat-at-Home Trend in Q3 Results

Campbell Soup Sees Boost from Eat-at-Home Trend in Q3 Results

7 minutes agoCPB

Campbell Soup Company recently revealed a 7% rise in net sales to $2.13 billion for its third-quarter fiscal 2024, thanks to inflation-driven pricing and sales allowances. This growth comes even as Campbell faces some volume declines due to supply challenges. Additionally, the company reported a significant 9% increase in organic net sales when excluding the sale of the Plum baby food and snacks business. Supporting these robust sales, Campbell Soup's adjusted gross margin improved by 90 basis points, reaching 31.5%. This improvement is attributed to supply chain productivity and successful cost-saving measures. However, the company's adjusted earnings per share dipped to $0.44 from $0.53 in the previous year, partly due to $0.30 per share in costs associated with savings initiatives and the acquisition of Sovos Brands. According to industry reports, costs related to this acquisition totaled $93 million, covering restructuring and other expenses. Campbell's focus on soups and frozen meals, paired with the recent Sovos Brands acquisition, has led to an updated annual sales forecast of 3%-4% growth, Reuters notes. Campbell Soup is pushing forward with strategic initiatives, particularly its cost savings plan expected to generate $1 billion in annual savings by the end of 2025. These efforts align with the company's broader strategy to tap into the growing popularity of at-home dining, expanding its product range and improving operational efficiencies.

Cleveland-Cliffs Stock Jumps as Trump Bumps Up Steel Tariffs

Cleveland-Cliffs Stock Jumps as Trump Bumps Up Steel Tariffs

22 minutes agoCLF

Cleveland-Cliffs Inc. (CLF) saw its stock price climb following President Donald Trump's announcement to double tariffs on imported steel and aluminum to 50%. The tariffs, set to take effect on June 4, 2025, are aimed at protecting domestic industries from perceived unfair trade practices. On June 2, in premarket trading, U.S. steel companies including Cleveland-Cliffs enjoyed notable share gains, Reuters reported. The tariff increase has sparked trade tension concerns, as it potentially leads to higher steel prices affecting industries such as construction and automobiles. These changes come amid international criticism, with countries like Canada and Australia warning of economic repercussions and considering retaliatory measures. Cleveland-Cliffs has openly supported the tariff escalation, seeing it as advantageous for the U.S. steel sector. As of June 2, 2025, their stock traded at $5.83, reflecting the market's response to the tariff news. Their recent backing of the administration's decision underscores the company's strategy to capitalize on favorable domestic policy shifts.

JetBlue and United Airlines Launch 'Blue Sky' Partnership

JetBlue and United Airlines Launch 'Blue Sky' Partnership

37 minutes agoJBLU

JetBlue Airways and United Airlines have jointly announced an exciting new collaboration called 'Blue Sky' that allows their passengers to book flights on both airlines' websites and offers reciprocal frequent flyer benefits. This strategic partnership is set to enhance travel connectivity for customers without the complexities of a full merger. Contrary to recent speculation, Joanna Geraghty, CEO of JetBlue, has made it clear that the airline is not pursuing a merger with United Airlines. Addressing concerns, she emphasized their cautious approach, highlighting that JetBlue has been particularly mindful of regulatory scrutiny, especially after its blocked merger attempt with Spirit Airlines. This approach aims to keep the airline's operations in line with the U.S. Department of Justice's antitrust considerations, as reported by Reuters. The 'Blue Sky' initiative focuses on expanding the airlines' networks and improving customer experiences through their collaborative efforts. By allowing passengers to enjoy the benefits of both airlines' frequent flyer programs and providing seamless booking options, JetBlue and United are delivering greater value to travelers while carefully navigating the regulatory landscape.

Bristol-Myers Squibb Joins Forces with BioNTech in $11 Billion Cancer Drug Collaboration

Bristol-Myers Squibb Joins Forces with BioNTech in $11 Billion Cancer Drug Collaboration

52 minutes agoBMY

Bristol-Myers Squibb (BMS) has struck a major partnership with BioNTech SE to develop and market BNT327, an emerging drug aimed at cancer treatment. As part of this deal, BMS will make an initial payment of $1.5 billion to BioNTech. Reuters reported that this expansive agreement could potentially reach a total value of approximately $11 billion. Further details reveal that BMS may provide up to $2 billion in non-contingent anniversary payments by 2028, while BioNTech stands to receive up to $7.6 billion tied to milestone achievements in the drug's development. The focal point of this deal, BNT327, is a bispecific antibody that targets PD-L1 and VEGF-A proteins to boost the immune system's ability to detect tumors and slow their progression. The drug is currently being tested in more than 20 clinical trials, including two late-stage studies focused on various solid tumors. This collaboration with BioNTech is part of BMS's broader strategy to enhance its oncology portfolio, especially as patents for existing bestsellers like Opdivo and Eliquis near expiration. Meanwhile, BioNTech leverages its COVID-19 vaccine success to advance oncology treatments, including mRNA-based therapies and cutting-edge chemotherapy techniques. Such partnerships reflect a wider industry trend towards joint efforts in developing advanced cancer therapies.